InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.061 -0.064 (-51.20%)+
Announcement
Release
29 Oct 2025 9:42AM
Price at Release
$0.125
Full Release
download
Summary
Neurizon Therapeutics Limited reported significant progress in its quarterly update for the period ended 30 September 2025. Key achievements include the FDA lifting the clinical hold on NUZ-001, allowing its participation in the HEALEY ALS Platform Trial, and securing a global licensing agreement with Elanco Animal Health for critical data. The company also initiated commercial-scale manufacturing of NUZ-001 and received regulatory support through an Advance and Overseas Finding, securing a substantial cash rebate. Financially, Neurizon raised $5.2 million through a share placement and a $1.5 million loan, while its shares began trading on the OTCQB® Venture Market. The company also strengthened its intellectual property with a new Australian patent for NUZ-001.
Key Points
  • FDA lifted the clinical hold on the IND application for NUZ-001, allowing participation in the HEALEY ALS Platform Trial.
  • Neurizon entered an exclusive global licensing agreement with Elanco Animal Health, gaining access to non-clinical animal safety and GMP manufacturing data.
  • The 12-month Open-Label Extension study of NUZ-001 met its primary safety endpoint and showed potential long-term efficacy.
  • NUZ-001 manufacturing commenced at Catalent using full-scale commercial processes.
  • Awarded an Advance and Overseas Finding from AusIndustry, enabling a cash rebate of 43.5% on eligible overseas R&D expenditure.
  • Raised $5.2 million through a share placement along with a $1.5 million secured loan.
  • Common shares approved for trading on the OTCQB® Venture Market under the ticker NUZTF.
  • Australian patent granted for NUZ-001 for treating neurodegenerative diseases.
  • Net cash from operating activities was negative $3.668 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.